Prevalence of HCV among Gender and Age Groups by Gene Drive Molecular Platform
Keywords:
Prevalence, HCV, gender, age, Gene Drive molecular platformAbstract
With years of government and stakeholder lethargy, chronic Hepatitis C virus (HCV) infection might be seen as a quiet and unexamined murderer. The occurrence Hepatitis C virus diagnosis among blood donors in Anambra State was assessed using the Genedrive Molecular Platform and Acumen Antibody Strip. Four hundred participants made up the study's subjects; these were prospective blood donors who came to the laboratory to donate blood from Anambra State University Teaching Hospital, Awka. 60.70% of the participants were female, with 255 being female, while 39.50% (165) of the subjects were male. The participants' ages ranged from 18 to 50 years old, with a mean age of 34. 55 out of 420 people tested positive for HCV, making the research population's total prevalence of the virus 13.10%. In terms of gender stratification, the prevalence for men was 12.72% (12 out of 165), whilst the prevalence for women was marginally higher at 13.33% (34 out of 255). The age range of 31 to 35 years showed the highest prevalence of positive cases, making up 34.43% (21 out of 61) of all positive cases within that age range. With a frequency of 38.18% (21 out of 55), this age group likewise showed the highest overall prevalence among the positive cases. This results present the current prevalence of the HCV genome 15 years after its discovery.
References
Shepard, C.W., Finelli, L & Alter, M.J. (2005). Global epidemiology of hepatitis C virus infection. Lancet Infectious Disease.5:558–67.
McGovern SL, Caselli E, Grigorieff N, Shoichet BK (2002). "A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening". Journal of Medicinal Chemistry.45(8):171222. doi:10.1021/jm010533y.PMID 11931626.
Liang, T. J. (2009). Hepatitis B: The virus and disease. Hepatology, 49(S5), S13–S21. doi:10.1002/hep.22881Alter, M.J. (2007). Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology, 13(17):2436-41.
Bala, J.A., Kawo, A.H., Mukhtar, M.D., Sarki, A., Magaji, N., Aliyu, I.A., Sani, M.N. (2012). Prevalence of Hepatitis C Virus Infection among blood donors in some selected hospitals in Kano, Nigeria. International Research Journal of Microbiology, 3(6): 217 – 222.
Cavalcante, L. N., & Lyra, A. C. (2015). Predictive factors associated with hepatitis C antiviral therapy response. World journal of hepatology, 7(12), 1617–1631. https://doi.org/10.4254/wjh.v7.i12.1617
Cheraliez, S. Bouvier – Alias, M.; Rodriguez, C. Soulier, A., Poveda, Jo &Pawlotsky, J.M. (2013). The Cobas Ampliprep/cobasTagman HCV Test Version 2.0; Real – Time PCR Assay Accurately Quantifies Hepatitis C. Virus: Genotype 4 RNA. Journal of Clinical Microbiology. 51 (4), 1078 – 1082.
Dubuisson, Jean; Cosset, François-Loïc (2014). "Virology and cell biology of the hepatitis C virus life cycle – An update". Journal of Hepatology. 61 (1), S3–S13.
Achara, G. andSadovisky, R. (2000). Hepatitis C virus: An overview of Epidemiological factors and Natural History. Internal medicine world Report. 15: 1-27.
Friedrich-Rust, M., Zeuzem, S., Sarrazin, C.(2007). Current therapy for hepatitis C. International Journal of Colorectal Disease. 22(4):341-9.
Kesson, A. M. (2002). Diagnosis and Management of paediatric Hepatitis C Virus Infection. Journal ofpaediatric child Health. 38: 213-8,
Lam, N.C., Gotsch, P.B., Langan, R.C. (2010). Caring for pregnant women and newborns with hepatitis B or C. American Family Physician. 82(10):1225-9.
Maheshwari, A., Thuluvath, P.J. (2010). Management of acute hepatitis C. Clinical Liver Disease. 14(1):169-76
Graham, C. S. & Swan, T. (2015). A path to eradication of hepatitis C in low- and middle-income countries,” Antiviral Research, 119: 89–96.
Halim, N. K. &Ajayi, O. I. (2000). Risk Factors and sero- prevalence of Hepatitis C Antibody in Blood donors in Nigeria. East African Medical Journal. 77: 410-2.
Itskowitz, M. S. (2007). Hepatitis C: epidemiology, diagnosis, and management. ComprTher 33, 87–93.
Okeke, O.C., and Ajulu, A.C. (2018). Duration of dialysis increases risk of hepatitis C virus infections among hemodialysis patients in Anambra State, Nigeria. UniversaMedicina, 37(3): 173 – 180.
Sharma, S.A & Feld, J.J. (2014). Acute hepatitis C: management in the rapidly evolving world of HCV. Current Gastroenterology Report. 16: 371.
Lawal, M.A., Adeniyi, O.F., Akintan, P.E., Salako, A.O., Omotosho, O.S., Temiye, E.O. (2020). Prevalence of and risk factors for hepatitis B and C viral co-infections in HIV infected children in Lagos, Nigeria. PLOS ONE, 15(12): e0243656
Williams, R. (2006). Global challenges in liver disease. Hepatology. 44(3), 521-6.
Iyalla, C., Igbigbi, E. E., and Oboro,L.I. (2018). seroprevalence of antibodies to hepatitis c virus in newly diagnosed hiv-1/2 positive patients in a tertiary hospital in Port Harcourt Nigeria.
Kaito, M., Ishida, S., Tanaka, H., Horiike, S., Fujita, N., Adachi, Y., (2006) "Morphology of hepatitis C and hepatitis B virus particles as detected by immunogold electron microscopy". Medical Molecular Morphology. 39 (2): 63–71.
Majumdar, A., Kitson, M.T & Roberts, S.K. (2016). Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Alilment Pharmacology Therapy, 46: 1276–92.
Alao, O., Okwori, E andAraoye, M. (2010). The Sero-Prevalence of Hepatitis C Virus (HCV) Infection among Prospective Blood Donors inMakurdi, Nigeria. The Internet Journal of Infectious Diseases. 8(1), 20-25.
Maaroufi, A., Vince, A., Himatt, S. M. et al. (2017). Historical epidemiology of hepatitis C virus in select countries. Journal of Viral Hepatology. 24(Suppl. 2):8–24.
Muhibi, M.A., Ifeanyichukwu, M.O., Olawuyi, A.O., Abulude, A.A., Adeyemo, M.O., Muhibi, M.O. (2018). Surveillance of anti-HCV antibody amongst in-school youth in a Nigeria University. African Journal of Clinical and Environmental Microbiology, 20(1): 49 – 53.
Jibrin, B., Jiya, N.M &Ahmed, H. (2014). Seroprevalence of hepatitis C virus antibody and its associated risk factors in children with sickle cell anaemia. Sub-Saharan African Journal of Medicine. 1:20-5.
Ngwogu, A.C., Ngwogu, K.O., Onyemachi, P.E.N.(2018).Seroprevalence of Hepatitis C surface antigenemia among HIV-infected individuals in Aba, South-Eastern Nigeria. East African Medical Journal, 195(5): 1588 – 1594.
Odenigbo, C., Oguejiofor, C., Okonkwo, U., Asomugha, A., Ezeh, T., Okocha, E. (2010). Prevalence of antibodies to Hepatitis C virus in blood donors in Nnewi, South-Eastern Nigeria: in association with blood groups. The Internet Journal of Gastroenterology, 20(2): 1 – 6.
Adesina, O.A., Akinyemi, J.O., Ogunbosi, B.O., Michael, O.S., Awolude, O.A. andAdewole, I.F. (2016). Seroprevalence and factors associated with hepatitis C coinfection among HIV-positive pregnant women at the University College Hospital, Ibadan, Nigeria. Tropical Journal of Obstetrics and Gynaecology. 33:153-8
Ojule, A.C., Akani, C. I. and Opurum, H.C. (2008).Sero-prevalence of hepatitis C antibodies in pregnant women in Port Harcourt, Nigeria. Port Harcourt Medical Journal, 3 (1): 55-61
Achinge, G. I., Malu, A.O., Mbaave, P. T andBitto T.T. (2013). Prevalence of Hepatitis C in Makurdi, North Central Nigeria Journal of Dental and Medical Sciences Volume 7, Issue 5 PP 06-10
Seeger, C., & Mason, W. S. (2016). HBV replication, pathobiology and therapy: Unanswered questions. Journal of Hepatology, 64(1), S1– S3.
Ugah, U. I., Alo, M.N., Uchenna, C. G. (2021). Epidemiology of hepatitis b virus, hepatitis C virus and human immunodeficiency virus co-infection among asymptomatic persons resident in Alex Ekwueme federal university Ndufu-alike, Scientific African, 14: e00985.
